Want to see DWTX full AI Analyst Report?
Dogwood Therapeutics (DWTX) Stock Statistics & Valuation Metrics
Total Valuation
Dogwood Therapeutics has a market cap or net worth of $43.51M. The enterprise value is $45.47M.
- Market Cap
- $43.51M
- Enterprise Value
- $45.47M
Share Statistics
Dogwood Therapeutics has 33,992,554 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 33,992,554
- Owned by Insiders
- 84.85%
- Owned by Institutions
- 1.08%
Financial Efficiency
Dogwood Therapeutics’s return on equity (ROE) is -0.46 and return on invested capital (ROIC) is -32.09%.
- Return on Equity (ROE)
- -0.46
- Return on Assets (ROA)
- -0.38
- Return on Invested Capital (ROIC)
- -32.09%
- Return on Capital Employed (ROCE)
- -0.32
- Revenue Per Employee
- 0
- Profits Per Employee
- -4.28M
- Employee Count
- 8
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Dogwood Therapeutics is -0.14. Dogwood Therapeutics’s PEG ratio is -0.00.
- PE Ratio
- -0.14
- PS Ratio
- 0.00
- PB Ratio
- 0.64
- Price to FCF
- -2.88
- Price to Operating Cash Flow
- -2.89
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Dogwood Therapeutics had revenue of 0 and earned -34.26M in profits. Earnings per share was -4.32.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -27.97M
- Pretax Income
- -34.04M
- Net Income
- -34.26M
- EBITDA
- -34.03M
- Earnings Per Share (EPS)
- -4.32
Cash Flow
In the last 12 months, operating cash flow was -15.11M and capital expenditures -6, giving a free cash flow of -15.11M billion.
- Operating Cash Flow
- -15.11M
- Free Cash Flow
- -15.11M
- Free Cash Flow per Share
- -0.44
Dividends & Yields
Dogwood Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -34.72%
- Earnings Yield
- -82.50%
Stock Price Statistics
- Beta
- 1.97
- 52-Week Price Change
- -80.75%
- 50-Day Moving Average
- 1.68
- 200-Day Moving Average
- 1.97
- Relative Strength Index (RSI)
- 44.07
- Average Volume (3m)
- 70.10K
Important Dates
Dogwood Therapeutics upcoming earnings date is Nov 05, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- ―
Financial Position
Dogwood Therapeutics as a current ratio of 2.76, with Debt / Equity ratio of 0.22%
- Current Ratio
- 2.76
- Quick Ratio
- 2.76
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.19
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Dogwood Therapeutics has paid 221.10K in taxes.
- Income Tax
- 221.10K
- Effective Tax Rate
- -0.01
Enterprise Valuation
Dogwood Therapeutics EV to EBITDA ratio is -1.16, with an EV/FCF ratio of -2.25.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.16
- EV to Free Cash Flow
- -2.25
- EV to Operating Cash Flow
- -2.25
Balance Sheet
Dogwood Therapeutics has $9.61M in cash and marketable securities with $127.21K in debt, giving a net cash position of $9.48M billion.
- Cash & Marketable Securities
- $9.61M
- Total Debt
- $127.21K
- Net Cash
- $9.48M
- Net Cash Per Share
- $0.28
- Tangible Book Value Per Share
- -$0.03
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Dogwood Therapeutics is $13.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $13.50
- Price Target Upside
- 954.69% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 52.36%
Scores
- Smart Score
- 6
- AI Score
- 45
